September 30, 2026

How Do Biotechs Get Delisted from Nasdaq?

For biotechnology companies, a Nasdaq listing is often seen as a badge of legitimacy – conferring access to capital, visibility with institutional investors, and inclusion in the broader healthcare ecosystem.

Delisting, by contrast, is viewed with fear – partly because it deprives a biotech of the aforementioned benefits, and also because the process isn’t well understood.

However, although delistings are not rare, they almost always follow predictable, well-telegraphed processes rather than sudden shocks. As such, understanding how biotechs get delisted from Nasdaq – and how long the process typically takes – is important for management teams, boards, and investors alike.

The most common path: minimum bid price deficiency

By far the most frequent reason biotechs are delisted is failure to maintain Nasdaq’s $1.00 minimum bid price requirement.

If a stock trades below $1.00 for 30 consecutive business days, Nasdaq issues a deficiency notice. This is not a delisting – it is a warning. The company is then given an initial 180-day period to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.

If compliance is regained, the issue disappears. If not, many biotechs qualify for a second 180-day extension, provided they meet other listing requirements and commit to a remedy – most commonly a reverse stock split.

Reverse stock splits: a common – but imperfect – solution

To cure a bid price deficiency, boards often approve a reverse stock split. This mechanically raises the share price but does nothing to address underlying fundamentals.

Nasdaq allows reverse splits, but it also scrutinizes repeat offenders. Companies that conduct multiple reverse splits in short succession may still face delisting if Nasdaq believes the action does not represent a sustainable solution.

Moreover, reverse stock splits are neither costless nor immediate – they actually involve a meaningful amount of time and money to execute – leaving distressed companies sometimes unable to afford, or with inadequate time to enact, such a remedy.

Market capitalization and equity requirements

Nasdaq also requires companies to maintain minimum stockholders’ equity, market value, or net income thresholds, depending on which Nasdaq tier they are listed on.

Clinical failures, cash burn, or prolonged market weakness can erode equity below required levels. When that happens, Nasdaq again issues a deficiency notice, followed by a compliance window.

For cash-burning biotechs with no revenue, this is a common secondary risk – particularly after failed trials, when both the share price and the balance sheet deteriorate simultaneously.

Failure to file financials

Another path to delisting is failure to file timely SEC reports.

If a biotech fails to file its Form 10-K or 10-Q on time, Nasdaq issues a deficiency notice. While short extensions are common, prolonged non-compliance signals deeper operational or financial distress.

Companies emerging from restructuring, auditor disputes, or internal control failures are particularly vulnerable here.

Voluntary delistings and mergers

Of course, not all delistings are punitive. Some biotechs choose to voluntarily delist, often in connection with:

• A merger or acquisition.
• A transition to private ownership.
• A liquidation or wind-down.

In these cases, the Nasdaq delisting is procedural rather than disciplinary. The key difference is that shareholders are typically cashed out or transitioned into another security.

Appeals and hearings

Companies facing delisting can appeal and request a Nasdaq hearing. This can delay delisting for several months, but it is not a guarantee of survival.

Nasdaq evaluates whether the company has a credible, executable plan to regain compliance, with vague optimism rarely being sufficient.

The end of an extended period of underperformance

To reiterate: delisting from Nasdaq is rarely sudden. It is usually the result of extended underperformance, signaled months – sometimes even years – in advance through deficiency notices and disclosures.

For biotech management teams, the real work is not avoiding the notice, but addressing the root causes early: capital structure, runway, credibility, and execution.

Successful biotechs are usually never delisted, typically just the ones that have suffered repeated failures with their drug development.

For more information go to: https://listingcenter.nasdaq.com/assets/continuedguide.pdf